Results 91 to 100 of about 102,367 (298)

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity

open access: yesJournal of Community Hospital Internal Medicine Perspectives, 2018
Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation ...
Adnan Asif Parvez Ghias   +3 more
doaj   +1 more source

Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects

open access: yesClinical and Translational Science, 2022
For the long‐term efficacy of dry eye disease treatment, relieving underlying inflammation is necessary. Imatinib mesylate is a novel ophthalmic formulation of imatinib mesylate, which is expected to alleviate inflammation by inhibiting the discoidin ...
Joo Young Na   +7 more
doaj   +1 more source

Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]

open access: yes, 2008
Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad   +4 more
core   +1 more source

Erratum to: Exploiting the promiscuity of imatinib [PDF]

open access: yesBMC Biology, 2010
An error in the PDB code occurred in the article published in the Journal of Biology [1]. In the legend to Figure One, instead of 1FW3, the correct PDB code is 3FW1.
Lee, Shun J, Wang, Jean YJ
openaire   +5 more sources

Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro. [PDF]

open access: yesPLoS ONE, 2011
Imatinib Mesylate (Gleevec) is a drug that potently counteracts diabetes both in humans and in animal models for human diabetes. We have previously reported that this compound in human pancreatic islets stimulates NF-κB signaling and islet cell survival.
Dariush Mokhtari   +3 more
doaj   +1 more source

Combined population dynamics and entropy modelling supports patient stratification in chronic myeloid leukemia [PDF]

open access: yes, 2016
Modelling the parameters of multistep carcinogenesis is key for a better understanding of cancer progression, biomarker identification and the design of individualized therapies.
Brehme, Marc   +7 more
core   +1 more source

BCR::ABL1‐Positive Acute Myeloid Leukemia

open access: yes
American Journal of Hematology, EarlyView.
Alban Canali   +3 more
wiley   +1 more source

In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Olivier Schueller   +4 more
wiley   +1 more source

Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. [PDF]

open access: yes, 2016
CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue.
Calabretta, Bruno   +10 more
core   +2 more sources

Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia [PDF]

open access: yesOncotarget, Impact journals, 2018, 2019
Background: Chronic myeloid leukemia (CML) results from hematopoietic stem cell transformation by the bcr-abl chimeric oncogene, encoding a 210 kDa protein with constitutive tyrosine kinase activity. In spite of the efficiency of tyrosine kinase inhibitors (TKI; Imatinib), other strategies are explored to eliminate CML leukemia stem cells, such as ...
arxiv  

Home - About - Disclaimer - Privacy